Champions Oncology is engaged in research and development technology solutions and services to improve the development and use of oncology drugs. Co.'s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. Co. uses this technology to provide solutions for the following consumer groups: Translational Oncology Solutions, which utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process; and Personalized Oncology Solutions, which provides physicians and patients information to help guide the development of personalized treatment plans. The CSBR stock yearly return is shown above.
The yearly return on the CSBR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CSBR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|